Matt D Wasserman

List of Publications by Year
in descending order

29	305	1051969 10	1051228 16
papers	citations	h-index	g-index

30	30	30	193
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019). Expert Review of Vaccines, 2022, 21, 885-898.	2.0	5
2	The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert Review of Vaccines, 2022, 21, 499-511.	2.0	4
3	Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine, 2022, 40, 4700-4708.	1.7	20
4	Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Human Vaccines and Immunotherapeutics, 2021, 17, 1162-1172.	1.4	9
5	Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Human Vaccines and Immunotherapeutics, 2021, 17, 909-918.	1.4	10
6	Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children. Emerging Infectious Diseases, 2021, 27, 1627-1636.	2.0	24
7	Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data. Infectious Diseases and Therapy, 2021, 10, 521-539.	1.8	20
8	Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia. Infectious Diseases and Therapy, 2021, 10, 507-520.	1.8	11
9	Reply letter to â€œresponse to article by Johnna Perdrizet et al.â€•by Gomez and colleagues. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	1.4	1
10	Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India. Infectious Diseases and Therapy, 2021, 10, 2271-2288.	1.8	1
11	Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium. Infectious Diseases and Therapy, 2021, 10, 1765-1778.	1.8	5
12	Letter to the editor regarding â€œBudget impact analysis of pneumococcal conjugate vaccines in Colombiaâ€• Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-3.	0.7	1
13	Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert Review of Vaccines, 2021, 20, 1-19.	2.0	8
14	Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious Diseases and Therapy, 2021, 10, 2701-2720.	1.8	11
15	Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. Vaccine, 2020, 38, 7138-7145.	1.7	23
16	Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis. Infectious Diseases and Therapy, 2020, 9, 305-324.	1.8	14
17	Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis. Infectious Diseases and Therapy, 2020, 9, 341-353.	1.8	7
18	Modelling the global impact of the 13-valent pneumococcal vaccine on antibiotic use for otitis media. European Journal of Public Health, 2020, 30, .	0.1	0

#	Article	IF	Citations
19	Comment on Gomez et. al. â€œResponse to article by Wasserman et. al. (2018) â€˜Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexicoâ€™â€•. Human Vaccines and Immunotherapeutics, 2019, 15, 572-574.	1.4	1
20	Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium. Infectious Diseases and Therapy, 2019, 8, 1-3.	1.8	4
21	Trends in vaccine investment in middle income countries. Human Vaccines and Immunotherapeutics, 2019, 15, 2378-2385.	1.4	7
22	Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Human Vaccines and Immunotherapeutics, 2019, 15, 560-569.	1.4	19
23	Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria. Infectious Diseases and Therapy, 2019, 8, 63-74.	1.8	11
24	Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India. Value in Health Regional Issues, 2018, 15, 99-105.	0.5	5
25	Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines, 2018, 17, 71-78.	2.0	21
26	Response to McGirr et al.'s Comment on â€œClinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canadaâ€•. Infectious Diseases and Therapy, 2018, 7, 539-543.	1.8	3
27	Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy, 2018, 7, 353-371.	1.8	29
28	Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS ONE, 2018, 13, e0201245.	1.1	18
29	Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiology and Infection, 2018, 146, 1797-1806.	1.0	13